SophiA GENETICS Launches New Residual Acute Myeloid (RAM) Application

New app supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse

BOSTON and ROLES, Switzerland, June 24, 2024 /PRNewswire/ — SophiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced its new Residual Acute Myeloid (RAM) App. The new offering expands the company’s comprehensive oncology portfolio to support measurable residual disease (MRD) capabilities and will be available to customers worldwide this summer.

Acute myeloid leukemia (AML) represents about one percent of all cancers worldwide, yet it is one of the most common forms of leukemia in adults.¹. Over 50 percent of AML patients relapse within 3 years of achieving complete remission²therefore post-treatment monitoring is essential for AML patients, especially within the first two years, to help detect any signs of relapse quickly³. MRD solutions can help inform post-remission therapy and identify early relapse and serve as a primary endpoint in clinical trials, helping researchers detect even the tiniest trace of cancer and support better outcomes. the patient.

“LAM unfortunately still remains an area of ​​high unmet medical need today, with suboptimal patient outcomes. Measuring and monitoring MRD has a critical role to play, for example enabling research into the most optimal sequence of therapies ,” said Philippe Menu, MD. , PhD., Chief Medical Officer and Chief Product Officer, Sophia GENETICS. “We are proud to contribute to the fight against AML through our SOPhiA DDM™ RAM solution. In particular we feel that the ability to seamlessly track the longitudinal evolution of individual mutations over time through a dedicated add-on module of our SOPHIA DDM platform ™ has the potential to be a game changer for clinical researchers.”

Next-generation sequencing (NGS)-based MRD testing is among the most advanced in cancer screening and monitoring and can only be found with highly sensitive methods. The SOPhiA DDM™ RAM solution provides users with the confidence that MRD will detect even one cancer cell among 10,000 cells. This app will allow users to stay ahead of disease response with the analytical capabilities of the SOPHIA DDM™ Platform, enabling the detection of sensitive variants down to 0.01% VAF and covering guideline-recommended genes to provide insight into strong for residual acute myeloid.

Customers using the SOPhiA DDM™ RAM solution will have access to longitudinal variant monitoring, allowing them to visualize the mutational landscape for each patient and its evolution over time. The solution also provides users with the most up-to-date databases and customizable reporting features to generate comprehensive MRD graphical representations and reports.

Additionally, the SOPhiA DDM™ RAM solution will continuously improve its machine learning algorithms to deliver the most accurate MRD results in as little as four days.

Representatives from SOPhiA GENETICS are available at AMP (Association for Molecular Pathology) Europe June 24-27 to discuss LPP monitoring with this new application.

For more information on SophiA GENETICS, visit SOPHiAGENETICS.com and connect on LinkedIn.

About Sophia GENETICS
SOPHIA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company with a mission to expand access to data-driven medicine using AI to deliver world-class care to patients with cancer and health disorders. rare across the globe. It is the creator of the SOPhiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time actionable insights for a vast global network of hospital, laboratory and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.

SophiA GENETICS products are for research use only and not for use in diagnostic procedures, unless otherwise specified. The information in this press release relates to products that may or may not be available in various countries and, if applicable, may or may not have received approval or market authorization from a government regulatory body for indications different for use. Please contact [email protected] to get the right product information for your country of residence.

Sophia GENETICS Forward-Looking Statement:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical fact contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products and technology, and management’s plans and objectives for operations future, are forward-looking. statements. Forward-looking statements are based on the beliefs and assumptions of our management and information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in forward-looking statements due to various factors, including those described in our filings with the Securities and Exchange Commission. USA. No assurance can be given that such results will be achieved in the future. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any changes in our expectations or any changes in the events, conditions or circumstances on which such statements are based, except as required to do so. do so by force. the law. No representation or warranty (express or implied) is given as to the accuracy of any such forward-looking statements.

SOURCE SophieA GENETICS